We are excited to announce that Sir Andrew Pollard will be joining the Oxford Leadership Program as an instructor again this summer!
Sir Andrew is the Director of the Oxford Vaccine Group in the Department of Paediatrics at the University of Oxford, and has participated in the ELO Oxford Leadership Program as an instructor in 2022.
Sir Andrew was the chief investigator for the clinical trials of the Oxford-AstraZeneca COVID-19 vaccine in 2020, which led to the authorisation of the vaccine for use in more than 180 countries with over 3 billion doses distributed.
Sir Andrew's presentation and Q & A session will focus on understanding how a product goes from inception to being administered 3 billion times in over 180 countries. What is the process of the commercialization of a product? What is role of partners such as Oxford Science Enterprises? Also, in hindsight, what are lessons learned? He will also discuss the role of science in society and how it's reliability has been challenged.
Dr. Richard (Rick) J. Goossen, Chairman, ELO, noted: “Sir Andrew’s involvement adds to a world-class roster of presenters from the University of Oxford, along with leading practitioners, which further solidifies ELO’s vision to deliver the premier executive education experience for Christian marketplace and entrepreneurial leaders.”
Sir Andrew is Director of the Oxford Vaccine Group in the Department of Paediatrics at the University of Oxford and a consultant paediatrician at Oxford Children’s Hospital and Fellow of St Cross College. He received a knighthood in the Queen’s Birthday Honours in 2021 for services to Public Health, especially in the pandemic, and received the Order of Medical Merit (Grande Oficial) from the Federal Republic of Brazil in 2022 and is Commander of the Order of Rio Branco.
He received the “Science Honor and Truth Award” of the Instituto de Patologia en la Altura in La Paz, Bolivia in 2002; the Bill Marshall Award of the European Society for Paediatric Infectious Disease (ESPID) in 2013; the ESPID Distinguished Award for Education and Communication in 2015; the Rosén von Rosenstein medal in 2019 awarded by the Swedish Paediatric Society and the Swedish Society of Medicine; and the Oxford University Vice Chancellor’s Innovation Award in 2020 for his work on typhoid vaccines. He was elected to the Academy of Medical Sciences in 2016 (member of Council 2022-2025) and the Royal Society in 2024 (member of Council 2025-2028). He was awarded honorary membership of the British Society for Immunology in 2021 and Associate membership of the National School of Healthcare Science (2022). He received the James Spence Medal of the Royal College of Paediatrics and Child Health in June 2022 and the 2023 IVI-SK bioscience Park MahnHoon Award.
He previously chaired the scientific panel of the Spencer Dayman Meningitis Laboratories Charitable Trust (2002-2006) and was a member of the scientific committee of the Meningitis Research Foundation (2009-2014) and is currently chair of trustees of the Knoop Trust, a Visitor at the Oxford History of Science Museum and a trustee of the Jenner Vaccine Foundation and the Oxford Philharmonic Orchestra Trust. He made the first British ascent of Jaonli (6632m) in 1988 and Chamlang in 1991 (7309m), was the Deputy leader of the successful 1994 British Medical Everest Expedition and climbed Kilimanjaro (5895m) in 2023.
Dr. Goossen previously posted four blog posts on the story of the Oxford-AstraZeneca vaccine:
ELO, Oxford & AstraZeneca COVID-19 Vaccine: How to Go from Idea to Opportunity? (Part I)
ELO, Oxford & AstraZeneca COVID-19 Vaccine: How to Solve a Global Problem? (Part II)
ELO, Oxford & AstraZeneca COVID-19 Vaccine: What's The Deal? (Part III)
ELO, Oxford & AstraZeneca COVID-19 Vaccine: How to Execute? (Part IV)
Interested in attending the Oxford Leadership Program?
